AstraZeneca logo

AZN - AstraZeneca Share Price

7831p -47.0  -0.6%

Last Trade - 11:34am

Sector
Healthcare
Size
Large Cap
Market Cap £103.37bn
Enterprise Value £114.81bn
Revenue £18.56bn
Position in Universe 11th / 1834
Bullish
Bearish
Unlock AZN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AZN Revenue Unlock AZN Revenue

Net Income

AZN Net Income Unlock AZN Revenue

Normalised EPS

AZN Normalised EPS Unlock AZN Revenue

PE Ratio Range

AZN PE Ratio Range Unlock AZN Revenue

Dividend Yield Range

AZN Dividend Yield Range Unlock AZN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AZN EPS Forecasts Unlock AZN Revenue
Profile Summary

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated June 17, 1992
Public Since September 21, 2007
No. of Shareholders: 83,588
No. of Employees: 64,400
AZN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AZN
Upcoming Events for AZN
Friday 14th February, 2020
Full Year 2019 AstraZeneca PLC Earnings Release
Friday 24th April, 2020 Estimate
AstraZeneca PLC Annual Shareholders Meeting
Wednesday 29th April, 2020
Q1 2020 AstraZeneca PLC Earnings Release
Similar to AZN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.